V Banerji

Max Rady Faculty of Health Sciences, College of Medicine, University of Manitoba, and Research Institute in Oncology and Hematology, and CancerCare Manitoba, Winnipeg, MB, Canada
Authored Items
Patient-Reported Outcomes from the Phase 3, Randomized Study of Acalabrutinib with or without Obinutuzumab versus Chlorambucil plus Obinutuzumab for Treatment-Naive Chronic Lymphocytic Leukemia (ELEVATE-TN)
P Walker , JP Sharman, W Jurczak, T Munir, V Banerji, S Coutre, JA Woyach, G Salles, WG Wierda, P Patel, MH Wang, U Emeribe, E Flood, JC Byrd, P Ghia
December 16, 2021 | December 2021 Vol 12, No 12
Last modified: December 17, 2021

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
SUBSCRIBE

Contact Us | Editorial Board

© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512